Tau Beats Amyloid in Predicting Brain Atrophy in Alzheimer Disease: Implications for Prognosis and Clinical Trials.
作者信息
Malpetti Maura, Joie Renaud La, Rabinovici Gil D
机构信息
Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California;
Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom; and.
出版信息
J Nucl Med. 2022 Jun;63(6):830-832. doi: 10.2967/jnumed.121.263694.
Abstract
摘要
相似文献
1
Tau Beats Amyloid in Predicting Brain Atrophy in Alzheimer Disease: Implications for Prognosis and Clinical Trials.在预测阿尔茨海默病脑萎缩方面，tau蛋白比淀粉样蛋白更具优势：对预后和临床试验的启示
J Nucl Med. 2022 Jun;63(6):830-832. doi: 10.2967/jnumed.121.263694.
2
Association of Sleep Disturbances With Brain Amyloid and Tau Burden, Cortical Atrophy, and Cognitive Dysfunction Across the AD Continuum.睡眠障碍与 AD 连续谱中脑淀粉样蛋白和 tau 负担、皮质萎缩和认知功能障碍的关系。
Neurology. 2023 Nov 21;101(21):e2162-e2171. doi: 10.1212/WNL.0000000000207917. Epub 2023 Oct 9.
3
Relationship between atrophy and beta-amyloid deposition in Alzheimer disease.阿尔茨海默病中萎缩与β-淀粉样蛋白沉积的关系。
Ann Neurol. 2010 Mar;67(3):317-24. doi: 10.1002/ana.21955.
4
Cerebrospinal fluid markers including trefoil factor 3 are associated with neurodegeneration in amyloid-positive individuals.脑脊液标志物，包括三叶因子 3，与淀粉样蛋白阳性个体的神经退行性变有关。
Transl Psychiatry. 2014 Jul 29;4(7):e419. doi: 10.1038/tp.2014.58.
5
Association of Seizure Foci and Location of Tau and Amyloid Deposition and Brain Atrophy in Patients With Alzheimer Disease and Seizures.阿尔茨海默病伴癫痫患者的癫痫病灶与tau和淀粉样蛋白沉积位置及脑萎缩的关联
Neurology. 2024 Nov 12;103(9):e209920. doi: 10.1212/WNL.0000000000209920. Epub 2024 Sep 27.
6
Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease.典型和非典型阿尔茨海默病中 tau、淀粉样蛋白、代谢和萎缩的影像学相关性。
Alzheimers Dement. 2018 Aug;14(8):1005-1014. doi: 10.1016/j.jalz.2018.02.020. Epub 2018 Mar 30.
7
Related amyloid burden and cortical atrophy in individuals with subtle cognitive decline.个体认知功能轻度下降与相关淀粉样蛋白负担和皮质萎缩。
J Neuroimaging. 2022 Nov;32(6):1075-1079. doi: 10.1111/jon.13055. Epub 2022 Sep 23.
8
Mapping the association between tau-PET and Aβ-amyloid-PET using deep learning.利用深度学习绘制 tau-PET 与 Aβ-amyloid-PET 的关联图。
Sci Rep. 2022 Aug 30;12(1):14797. doi: 10.1038/s41598-022-18963-6.
9
Borrelia burgdorferi Co-Localizing with Amyloid Markers in Alzheimer's Disease Brain Tissues.伯氏疏螺旋体与阿尔茨海默病脑组织中的淀粉样标记物共存。
J Alzheimers Dis. 2022;85(2):889-903. doi: 10.3233/JAD-215398.
10
Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.与临床前阿尔茨海默病核心 CSF 生物标志物相关的纵向结构脑变化：两项独立数据集研究。
Neuroimage Clin. 2018 Apr 16;19:190-201. doi: 10.1016/j.nicl.2018.04.016. eCollection 2018.
引用本文的文献
1
Whole-brain functional connectivity predicts regional tau PET in preclinical Alzheimer's disease.全脑功能连接可预测临床前阿尔茨海默病患者的区域tau正电子发射断层扫描结果。
Brain Commun. 2025 Jul 15;7(4):fcaf274. doi: 10.1093/braincomms/fcaf274. eCollection 2025.
2
P2RX7 regulates tauopathy progression via tau and mitochondria loading in extracellular vesicles.P2RX7通过细胞外囊泡中的tau蛋白和线粒体负载来调节tau蛋白病的进展。
Res Sq. 2025 Jun 23:rs.3.rs-6771517. doi: 10.21203/rs.3.rs-6771517/v1.
3
[I]IPPI for Tau Imaging: Binding Studies in Postmortem Human Alzheimer's Disease Hippocampus-Subiculum and Evaluation of Drug Effects.[I]用于tau成像的IPPI：对死后人类阿尔茨海默病海马-下托的结合研究及药物效果评估。
Synapse. 2025 Jul;79(4):e70024. doi: 10.1002/syn.70024.
4
The R136S mutation in the APOE3 gene confers resilience against tau pathology via inhibition of the cGAS-STING-IFN pathway.载脂蛋白E3（APOE3）基因中的R136S突变通过抑制环鸟苷酸-腺苷酸合成酶-干扰素基因刺激蛋白（cGAS-STING-IFN）信号通路赋予对tau病理的抵抗力。
Immunity. 2025 Jun 23. doi: 10.1016/j.immuni.2025.05.023.
5
Computational Risk Stratification of Preclinical Alzheimer's in Younger Adults.年轻成年人临床前阿尔茨海默病的计算风险分层
Diagnostics (Basel). 2025 May 26;15(11):1327. doi: 10.3390/diagnostics15111327.
6
Lemborexant ameliorates tau-mediated sleep loss and neurodegeneration in males in a mouse model of tauopathy.在tau蛋白病小鼠模型中，lemborexant可改善雄性小鼠tau蛋白介导的睡眠丧失和神经退行性变。
Nat Neurosci. 2025 May 27. doi: 10.1038/s41593-025-01966-7.
7
Polyamination with spermidine enhances pathogenic tau conformations while reducing filamentous aggregate formation in vitro.用亚精胺进行多胺化反应可增强致病性tau构象，同时在体外减少丝状聚集体的形成。
Biochem J. 2025 Jun 17;482(12):877-99. doi: 10.1042/BCJ20253079.
8
Development of Simple Risk Scores for Prediction of Brain β-Amyloid and Tau Status in Older Adults With Mild Cognitive Impairment: A Machine Learning Approach.用于预测轻度认知障碍老年人脑β淀粉样蛋白和tau蛋白状态的简单风险评分的开发：一种机器学习方法。
J Gerontol B Psychol Sci Soc Sci. 2025 Jun 10;80(7). doi: 10.1093/geronb/gbaf085.
9
Uncovering atrophy progression pattern and mechanisms in individuals at risk of Alzheimer's disease.揭示阿尔茨海默病高危个体的萎缩进展模式及机制。
Brain Commun. 2025 Mar 4;7(2):fcaf099. doi: 10.1093/braincomms/fcaf099. eCollection 2025.
10
Probe-dependent Proximity Profiling (ProPPr) Uncovers Similarities and Differences in Phospho-Tau-Associated Proteomes Between Tauopathies.基于探针的邻近分析（ProPPr）揭示了tau蛋白病之间磷酸化tau相关蛋白质组的异同。
Mol Neurodegener. 2025 Mar 13;20(1):32. doi: 10.1186/s13024-025-00817-0.
本文引用的文献
1
Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.基于生物标志物的阿尔茨海默病纵向 Tau 正电子发射断层扫描预测。
JAMA Neurol. 2022 Feb 1;79(2):149-158. doi: 10.1001/jamaneurol.2021.4654.
2
Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.血浆磷酸化 tau 217 和磷酸化 tau 181 作为阿尔茨海默病和额颞叶变性的生物标志物：一项回顾性诊断性能研究。
Lancet Neurol. 2021 Sep;20(9):739-752. doi: 10.1016/S1474-4422(21)00214-3.
3
Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.Tau 正电子发射断层扫描作为临床前和前驱期阿尔茨海默病预后标志物的准确性：与淀粉样蛋白正电子发射断层扫描和磁共振成像的头对头比较。
JAMA Neurol. 2021 Aug 1;78(8):961-971. doi: 10.1001/jamaneurol.2021.1858.
4
Four distinct trajectories of tau deposition identified in Alzheimer's disease.阿尔茨海默病中tau 沉积的四种不同轨迹。
Nat Med. 2021 May;27(5):871-881. doi: 10.1038/s41591-021-01309-6. Epub 2021 Apr 29.
5
Donanemab in Early Alzheimer's Disease.多奈单抗用于早期阿尔茨海默病
N Engl J Med. 2021 May 6;384(18):1691-1704. doi: 10.1056/NEJMoa2100708. Epub 2021 Mar 13.
6
Comorbid neuropathological diagnoses in early versus late-onset Alzheimer's disease.早发性与晚发性阿尔茨海默病的共病神经病理学诊断。
Brain. 2021 Aug 17;144(7):2186-2198. doi: 10.1093/brain/awab099.
7
Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology.血浆 p-tau231：早期阿尔茨海默病病理学的新生物标志物。
Acta Neuropathol. 2021 May;141(5):709-724. doi: 10.1007/s00401-021-02275-6. Epub 2021 Feb 14.
8
18F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases.18F-氟托西匹 PET 与阿尔茨海默病和其他神经退行性疾病的尸检比较。
Brain. 2020 Dec 5;143(11):3477-3494. doi: 10.1093/brain/awaa276.
9
Spatial Relationships between Molecular Pathology and Neurodegeneration in the Alzheimer's Disease Continuum.阿尔茨海默病连续体中分子病理学与神经退行性变的空间关系。
Cereb Cortex. 2021 Jan 1;31(1):1-14. doi: 10.1093/cercor/bhaa184.
10
Synergy between amyloid-β and tau in Alzheimer's disease.淀粉样蛋白-β与tau 在阿尔茨海默病中的协同作用。
Nat Neurosci. 2020 Oct;23(10):1183-1193. doi: 10.1038/s41593-020-0687-6. Epub 2020 Aug 10.
Zotero 插件